Levels of Serum IL-34 and Lipid profile in Type 2 Diabetes Mellitus Patients
Main Article Content
Keywords
IL-34, lipid profile, Inflammation, cardiovascular problems
Abstract
Diabetes mellitus type 2 (T2DM) is a growing global health issue that is inextricably related to the obesity epidemic. Because of hyperglycemia and individual components of the insulin resistance (metabolic) syndrome, people with T2DM are at a significant risk for both microvascular and macrovascular consequences. Environmental (fat, a poor diet, and physical inactivity, for example) and hereditary variables also contribute to the many pathophysiological disruptions that cause impaired glucose homeostasis in T2DMSeveral studies have been conducted to investigate the role of dyslipidaemia in the macrovascular complications of diabetes. The current investigation's purpose was to determine the prevalence, pattern, and the link between IL-34 and dyslipidemia in T2DM patients. This study involves sixty T2DM patients. 30 people who appear to be in good health served as the control. Both the patients and the controls are the same age and BMI. Lipid abnormalities were discovered in this research. T2DM is distinguished by a high frequency of dyslipidaemia. An increase in poor lipids causes a variety of problems, including cardiovascular disease (CVD). Inflammation causes the proinflammatory cytokine IL-34, which is more prevalent in T2DM patients. Abnormal lipids and IL-34 can be factors in cardiovascular disease.
References
2. Aljabri, S. Bokhari, S. and Akl, A. The relation between overweight, obesity and plasma lipids in
Saudi adults with type 2 diabetes. Jeddah J. Health. Spe., 4: 140-145 (2016).
3. American Heart Association. Cardiovascular Disease and Diabetes. [Internet]. 2015. Available from: https://www.heart.org/en/healthtopics/diabetes/why-diabetes-matters/cardiovascular-disease-diabetes. Accessed date: 13 March 2019.
4. Chang EJ, Lee SK ,Song YS,et al IL-34 is associated with obesity, chronic inflammation, and insulin resistance.J Clin Endocrinol Metab. 2014; 99: E1263-E1271
5. Demir, S., Nawroth, P. P., Herzig, S., & Ekim Üstünel, B. (2021). Emerging Targets in Type 2 Diabetes and Diabetic Complications. Advanced Science, 8(18), 1–23. https://doi.org/10.1002/advs.202100275
6. Dobiásová M, Frohlich J. The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma (FER(HDL)). Clin Biochem. 2001;34:583–588.
7. Garvey WT, Kwon S, Zheng D, Shaughnessy S, Wallace P and Hutto A et al. Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes;2003, 52:453-62).
8. Graves LE and Donaghue KC (2020) Vascular Complication in Adolescents with Diabetes Mellitus. Front. Endocrinol. 11:370.
9. Guerrero-Romero F, Simental-Mendía LE, González-Ortiz M, et al. The Product of Triglycerides and Glucose, a Simple Measure of Insulin Sensitivity. Comparison with the Euglycemic-Hyperinsulinemic Clamp. J Clin Endocrinol Metab. 2010;95:3347–3351 .
10. Guo Q. Q., Y. Y. Zheng, J. N. Tang et al., “Fasting blood glucose to HDL-C ratio as a novel predictor of clinical outcomes in non-diabetic patients after PCI,” Bioscience Reports, vol. 40, no. 12, p. 40, 2020.
11. Haffner SM, Mykkanen L, Festa A: Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects. Circulation. 2000, 101: 975-980. 10.1161/01.CIR.101.9.975.
12. Hu FB, Meigs JB, Li TY ,Rifai N, Manson JE. Inflammatory markers and risk of developing type 2 diabetes in women. Diabetes. 2004; 53: 693-700
13. Islam, M.S.; Qaraqe, M.K.; Belhaouari, S.B. Early Prediction of Hemoglobin Alc: A novel Framework for better Diabetes Management. In Proceedings of the 2020 IEEE Symposium Serieson Computational Intelligence (SSCI), Canberra, Australia, 1–4 December 2020; pp. 542–547.
14. James DE, Stöckli J, Birnbaum MJ. The aetiology and molecular landscape of insulin resistance. Nat Rev Mol Cell Biol(2021) 22, 751–771.
15. Jedda, W., Al-Ali, Z., & Akram, R. S. (2021). Study the Interferon–γ, C-reactive Protein and Lipid Profile in Iraqi Diabetic Patients With and Without Hypertension. Nveo-Natural Volatiles & …, 8(5), 8820–8832. http://www.nveo.org/index.php/journal/article/view/2310%0Ahttps://www.nveo.org/index.php/journal/article/download/2310/2035
16. Jian, Y., Pasquier, M., Sagahyroon, A., & Aloul, F. (2021). A machine learning approach to predicting diabetes complications. Healthcare (Switzerland), 9(12). https://doi.org/10.3390/healthcare9121712
17. Lin H, Lee E, Hestir K, et al. . Discovery of a cytokine and its receptor by functional screening of the extracellular proteome. Science. 2008;320:807–811
18. Mellbin LG, Wang A, Rydén L. Clinical implications of cardiovascular outcome trials in type 2 diabetes. Herz. 2019 May;44(3):192-202.
19. Meo SA, Usmani AM, Qalbani E. Prevalence of type 2 diabetes in the Arab world: impact of GDP and energy consumption. Eur Rev Med Pharmacol Sci. 2017 Mar;21(6):1303-1312.
20. Mostafa, T. M., El-Gharbawy, N. M., & Werida, R. H. (2021). Circulating IRAPe, Irisin, and IL-34 in Relation to Insulin Resistance in Patients With Type 2 Diabetes. Clinical Therapeutics. j.clinthera. 2021;19:3].
21. Oh, R. and Lanier, J. Management of hypertriglyceridemia. Am. Fam., 75: 1365-1371 (2007)
22. Piao C, Wang X, Peng S, Guo X, Zhao H, He L, Zeng Y, Zhang F, Zhu K, Wang Y. IL-34 causes inflammation and beta cell apoptosis and dysfunction in gestational diabetes mellitus. Endocr Connect. 2019 Nov;8(11):1503-1512.
23. Piya MK, McTernan PG, Adipokine Kumar S. inflammation and insulin resistance: the role of glucose, lipids and endotoxin. J Endocrinol. 2013;216:T1–T15.
24. Piya MK, McTernan PG, Adipokine Kumar S. inflammation and insulin resistance: the role of glucose, lipids and endotoxin. J Endocrinol. 2013;216:T1–T15.
25. Santos-Gallego CG, Rosenson RS. Role of HDL in those with diabetes. Curr Cardiol Rep. 2014;16(9):512. doi:10.1007/s11886-014-0512-5.
26. Seijkens T, Kusters P, Engel D, Lutgens E. CD40–CD40L: linking pancreatic, adipose tissue and vascular inflammation in type 2 diabetes and its complications. Diab Vasc Dis Res. 2013;10:115–122.
27. World Health Organization. Diabetes. Geneva, Switzerland: World Health Organization; 2018. https://www.who.int/news-room/fact-sheets/detail/diabetes. Updated October 30, 2018. Accessed March, 2019.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.